Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Multiple Myeloma 16Recurrence 2Lymphoma, Non-Hodgkin 2Smoldering Multiple Myeloma 1Renal Insufficiency 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Lymphoma 1Leukemia, Plasma Cell 1Hodgkin Disease 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 27fludarabine 18Rituximab 17obinutuzumab 11venetoclax 9Bendamustine Hydrochloride 9Lenalidomide 8zanubrutinib 6Prednisone 6Doxorubicin 6Blood Specimen Collection 6pembrolizumab 5fludarabine phosphate 5Biopsy 5ibrutinib 4glofitamab 4Vincristine 4Trimethoprim, Sulfamethoxazole Drug Combination 4Exercise 4loncastuximab tesirine 3gamma-Globulins 3axicabtagene ciloleucel 3acalabrutinib 3Temozolomide 3Surveys and Questionnaires 3Palliative Care 3Mycophenolic Acid 3Methotrexate 3Mesna 3Magnetic Resonance Spectroscopy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphoma × isatuximab × Clear all
NCT05346809 2025-06-08

Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma

Columbia University

Phase 2 Recruiting
39 enrolled
LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡